What question did this study set out to answer?

To evaluate the role and effectiveness of adjuvant therapy for patients with high-risk stage II melanoma and explore patient selection strategies.

June 3, 2026CancersOpen Access

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions

View Full Paper

Ask AI

Bookmark

To evaluate the role and effectiveness of adjuvant therapy for patients with high-risk stage II melanoma and explore patient selection strategies.
Review of current therapeutic options including pembrolizumab and nivolumab.
Assessment of immune checkpoint inhibitors and mRNA-based vaccines in clinical trials.
Analysis of clinicopathologic variables and gene expression profiling for risk stratification.
Pembrolizumab and nivolumab reduce the risk of local and distant recurrence in high-risk stage II melanoma.
Evidence for efficacy of BRAF-MEK inhibitors in this setting remains inconclusive.
No validated predictive biomarkers or instruments for routine clinical practice have been established.

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses adjuvant therapy effectiveness in high-risk stage II melanoma, indicating a need for improved patient selection.

Pravisano et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial assesses adjuvant therapy effectiveness in high-risk stage II melanoma, indicating a need for improved patient selection.